TOP > 外国特許検索 > SPECIFIC MODIFICATION OF ANTIBODY BY IgG-BINDING PEPTIDE

SPECIFIC MODIFICATION OF ANTIBODY BY IgG-BINDING PEPTIDE コモンズ 新技術説明会

外国特許コード F160008762
整理番号 14P058WO
掲載日 2016年6月2日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP065061
国際公開番号 WO 2016186206
国際出願日 平成28年5月20日(2016.5.20)
国際公開日 平成28年11月24日(2016.11.24)
優先権データ
  • 特願2015-103153 (2015.5.20) JP
発明の名称 (英語) SPECIFIC MODIFICATION OF ANTIBODY BY IgG-BINDING PEPTIDE コモンズ 新技術説明会
発明の概要(英語) The present invention pertains to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a complex of IgG and said IgG-binding peptide modified with a cross-linking agent, and a method for preparing said complex.
従来技術、競合技術の概要(英語) BACKGROUND ART
Antibodies, various types of research in the prior art, in the development, detection of target molecules often used and, to a surface of the industry as a detection reagent or diagnostic agents, and are extremely important. In addition, the antibody, specificity for its target molecule from the, also as a medicament for the treatment of disease has attracted attention.
For adding a function of the chemical modifications include, alkaline phosphatase or peroxidase (HRP) (AP) (non-patent document 1-2) such as enzymes, radioactive isotopes and further for iodinated and chelate compounds and the additional (non-patent document 3), a low molecular weight compound such as biotin modifications have been made by (non-patent document 4). These modifications are, mainly lysine amino groups and the thiol group of cysteine, and activated via a carboxyl group has been carried out, but these are specific for functional groups, is not site-specific, such as a modification to the antigen binding site of the antibody and a problem that reduce the activity of the, is difficult to control the number of compounds binding to the above described problem of the like. Antibody pharmaceuticals has recently emerged in antibody drug conjugates (ADC) (non-patent document 5-6), anti-cancer drugs for non-specific antibody which binds to a site, or the activity of the antibody itself is weakened, the anti-cancer agent due to the difficulty of control of the number of bonds subsequent formulation step was the problem of a complicated.
In order to overcome such a problem, site-specific specific functional groups introduced using antibodies, modified antibodies is performed. For example, non-natural amino acid cysteine or a free (non-patent document 7-9) to (non-patent document 10-11), genetically engineered by the modification of a specific site by introducing, at a specific site of modifications was possible. Using the transglutaminase (TG), a naturally occurring or artificially introduced into the in antibodies specific for modification of glutamine to target is reported (non-patent document 12-13), the structure of the compound and introducing, the glutamine residue of the target by a spatial environment is greatly affected the reaction yield is known. Further, on the sugar chain of the antibody Fc modified techniques can also be utilized to target and (non-patent document 14-15), these methods are site-specific but, since the oxide require modification of the sugar chain, the complexity of the reaction step which is problematic. In this way is site-specific modification of antibodies having been developed in the art, in many cases, the antibody itself need to be engineered antibody, with the modification of functions of the antibody does not necessarily have to consider the cost of development and not necessarily advantageous.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • 発明者(英語)
  • ITO Yuji
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
参考情報 (研究プロジェクト等) AMED Basic Science and Plateform Tachnolohgy Program for Innovative Biological Medicine AREA
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close